Financial reports
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
11 Apr 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
25 Mar 22
Current reports
8-K
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
14 Mar 24
8-K
Other Events
11 Mar 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
8-K
Termination of a Material Definitive Agreement
14 Feb 24
8-K
Results of Operations and Financial Condition
12 Feb 24
8-K
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
14 Nov 23
8-K
Departure of Directors or Certain Officers
3 Oct 23
8-K
Other Events
14 Aug 23
8-K
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
10 Aug 23
8-K
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
25 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
14 Mar 24
S-8
Registration of securities for employees
14 Mar 24
424B5
Prospectus supplement for primary offering
14 Feb 24
424B5
Prospectus supplement for primary offering
13 Feb 24
S-8
Registration of securities for employees
14 Mar 23
S-8
Registration of securities for employees
14 Mar 23
S-3
Shelf registration
10 Nov 22
424B5
Prospectus supplement for primary offering
14 Sep 22
S-8
Registration of securities for employees
2 Oct 20
S-3
Shelf registration
14 Aug 20
Proxies
PRE 14A
Preliminary proxy
12 Apr 24
DEF 14A
Definitive proxy
11 Apr 23
DEF 14A
Definitive proxy
12 Apr 22
DEF 14A
Definitive proxy
14 Apr 21
DEFA14A
Additional proxy soliciting materials
19 Aug 20
DEF 14A
Definitive proxy
19 Aug 20
DEFA14A
Additional proxy soliciting materials
18 May 20
DEFM14A
Proxy related to merger
29 Apr 20
PRER14A
Preliminary revised proxy
27 Apr 20
PRER14A
Preliminary revised proxy
10 Apr 20
Other
EFFECT
Notice of effectiveness
22 Nov 22
CORRESP
Correspondence with SEC
18 Nov 22
UPLOAD
Letter from SEC
16 Nov 22
EFFECT
Notice of effectiveness
2 Sep 20
CORRESP
Correspondence with SEC
31 Aug 20
UPLOAD
Letter from SEC
24 Aug 20
EFFECT
Notice of effectiveness
15 Jul 20
CORRESP
Correspondence with SEC
13 Jul 20
UPLOAD
Letter from SEC
10 Jul 20
UPLOAD
Letter from SEC
30 Apr 20
Ownership
SC 13D/A
Flynn James E
15 Mar 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
26 Feb 24
4
James E Flynn
16 Feb 24
SC 13D/A
Flynn James E
16 Feb 24
SC 13D/A
Flynn James E
15 Feb 24
4
FRANK E THOMAS
15 Feb 24
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G
Verition Fund Management LLC
14 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24